EL7.AI
StocksUpdated•Originally published 15 July 2026•Updated 16 July 2026•
1 min read

Cryo-Cell Profits Surge 56% in Q2 as FICO Sets Earnings Date

Key Facts

1Cryo-Cell reported revenues of $7.8 million for the fiscal second quarter ended May 31, 2026, a 2% decrease year-over-year.
2FICO announced it will report its third quarter fiscal 2026 results on July 29, 2026, after the market closes.

Reflecting a significant boost in operational efficiency despite sector headwinds, Cryo-Cell International reported a 56% surge in net income to $555,000 for the fiscal second quarter ending May 31, 2026. While revenues saw a slight 2% dip to $7.8 million, the company achieved earnings per share (EPS) of $0.07. Simultaneously, Fair Isaac Corporation (FICO) has scheduled its third-quarter fiscal earnings release for July 29, following the market close.

The robust growth in Cryo-Cell's bottom line effectively offsets the marginal revenue decline, suggesting successful cost-management strategies within the competitive cord blood banking industry. Meanwhile, FICO remains a focal point for investors due to its dominance in credit scoring; per market data, financial software peers have faced heightened scrutiny regarding margin sustainability amid shifting interest rate expectations and broader tech sector volatility.

Investors should closely track FICO shares, which stood at $1210.52 at the close of July 14, 2026, having reached a session high of $1258.96. The upcoming earnings report on July 29 stands as the primary catalyst in the economic calendar, likely determining the stock's trajectory and providing updated fiscal guidance for the second half of the year.